Neurolens, a company commercializing innovative solutions to optimize vision, recently completed a $67 million financing led by Troutman Pepper client MVM Partners, a life sciences investment fund focused on innovative health care companies in medical technology, pharmaceuticals, diagnostics, and digital health. Additional participants included Falcon Vision/KKR, Marshall Wace, and existing investors including Bluestem Capital. Read a company press release about the financing.

With patented Contoured Prism technology, Neurolens prescription lenses go beyond visual acuity to provide comfort for adults suffering headaches, neck/shoulder pain, and eyestrain when using digital devices, reading, or doing detail work.

The Troutman Pepper team advising MVM in the investment included Chris Miller, Dan Sieck, Celia Marcum, Joseph Goldman, Daniel Anziska, and Ethan Zook, among others.